Zambon Announces Breakthrough in Phase 3 Study for Lung Therapy
Zambon, a leading global pharmaceutical company focused on improving health and enhancing patients' lives, has made noteworthy progress in treating respiratory diseases. Recently, they released a study in a respected journal detailing the Phase 3 PROMIS-I and PROMIS-II trials. These studies demonstrate the effectiveness of inhaled colistimethate sodium when delivered through the advanced I-neb Adaptive Aerosol Delivery System. This innovative treatment aims to decrease the number of pulmonary exacerbations in patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) who are routinely infected with P. aeruginosa.
The Importance of the PROMIS Studies
The PROMIS studies are groundbreaking initiatives evaluating the effectiveness of inhaled colistimethate sodium, a well-known antibiotic in Europe, particularly for treating Cystic Fibrosis. These trials were designed to assess treatment over a year compared to a placebo, concentrating on critical measures like the rate of pulmonary exacerbations.
Key Data and Outcomes
“The release of this vital data demonstrates our commitment to driving forward new treatments for severe respiratory illnesses,” said Paola Castellani, Zambon's Chief Medical Officer and Head of R&D. “The PROMIS results highlight the potential of CMS I-neb to improve outcomes and enhance the quality of life for patients with NCFB, where effective treatment options are limited. We look forward to working with regulatory agencies to hasten patient access to this important therapy.”
Infections from P. aeruginosa can lead to serious disease progression, more exacerbations, hospital stays, and increased risk of death. The PROMIS trials represent the first large-scale, double-blind, placebo-controlled studies focusing on inhaled colistimethate sodium for this patient group.
Study Parameters and Findings
The findings came from global Phase 3 multicenter trials that randomly assigned adult bronchiectasis patients. The participants had experienced multiple exacerbations needing antibiotic treatment in the year before the study. There were 377 participants in PROMIS-I and 287 in PROMIS-II, receiving treatment regimens twice daily for up to a year.
Key Findings from PROMIS Trials
The PROMIS-I trial showed a notable reduction in annual exacerbation rates, with a decrease of 39% compared to those receiving placebo. Severe exacerbation rates also dropped significantly by 59%. Patients reported enhancements in quality-of-life metrics, measured by the St. George’s Respiratory Questionnaire, as well as a reduction in P. aeruginosa density in their airways.
Although the PROMIS-II study faced disruptions due to external circumstances, early sub-analysis revealed results similar to those in PROMIS-I. Additionally, participants in both trials tolerated the treatment well, with minimal safety concerns reported.
Expert Reactions to the Results
Experts are lauding the PROMIS program for its innovative implications. Dr. Charles Haworth, a respected respiratory physician, remarked, “These results mark a major advancement for NCFB patients, who have had few effective options available. This is the first time we demonstrate that CMS I-neb can significantly reduce exacerbations and improve quality of life, offering renewed hope for this underserved group.”
Professor James Chalmers added, “The findings underscore the significant role that inhaled antibiotics like CMS I-neb play in managing NCFB and the chronic infections that cause inflammation and lung damage. Reducing exacerbations is closely tied to better health outcomes and lung function.”
Zambon’s Ongoing Commitment
The PROMIS program has received recognition through FDA Fast Track and Breakthrough designations. These accolades aim to help minimize the burden of pulmonary exacerbations among adults with NCFB related to P. aeruginosa. They reflect Zambon’s unwavering commitment to advancing treatment options for respiratory illnesses.
Understanding NCFB and Its Treatment
Non-cystic fibrosis bronchiectasis is a rising chronic lung condition characterized by frequent infections and a persistent cough, primarily caused by Pseudomonas aeruginosa. As this condition becomes more prevalent globally, particularly among women and older individuals, the demand for effective treatment options grows. The main goals in managing bronchiectasis involve symptom control, prevention of exacerbations, and improving the quality of life for patients.
About Zambon
Zambon SpA, with its roots in Italy since 1906, is dedicated to providing innovative healthcare solutions. Employing over 2,500 professionals and operating in 23 countries, Zambon has a strong reputation for pioneering work across various therapeutic areas, ensuring that high-quality products reach patients in 87 markets. Their recent initiatives also address neurodegenerative disorders and rare diseases, alongside their established legacy in respiratory treatments.
Frequently Asked Questions
What are the PROMIS-I and PROMIS-II trials about?
The PROMIS trials are significant Phase 3 studies investigating inhaled colistimethate sodium for treating non-cystic fibrosis bronchiectasis, particularly focusing on patients with P. aeruginosa.
What did the results from the trials highlight?
The results indicated a reduction in pulmonary exacerbations and an improvement in quality of life among patients treated with CMS I-neb compared to placebo.
Who is Zambon and what do they focus on?
Zambon is a pharmaceutical company dedicated to enhancing healthcare, specifically innovating treatment options for respiratory and other chronic diseases.
Why is inhaled colistimethate sodium important?
Inhaled colistimethate sodium is crucial for those with NCFB as it targets chronic infections, reducing exacerbations and improving overall lung health.
What are the next steps for Zambon following these trials?
Zambon plans to collaborate with regulatory bodies to fast-track the availability of CMS I-neb for patients in need, ultimately improving treatment options for chronic respiratory diseases.
